Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance
01 mars 2017 07h00 HE
|
Akorn, Inc.
- Q4 2016 Revenue Increase to $284 Million - - Q4 2016 GAAP Diluted EPS Decrease of 4% to $0.26; Q4 2016 Adjusted Diluted EPS Decrease of 3% to $0.58 - - FY 2016 Revenue Increase of 13% to $1,117...
Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP
28 févr. 2017 17h30 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug...
Akorn to Report Fourth Quarter and Full Year 2016 Results
06 févr. 2017 07h30 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on...
Akorn to Present at 35th Annual J.P Morgan Healthcare Conference
21 déc. 2016 07h30 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn’s CEO, Raj Rai, will present at the...
Akorn Announces Completion of FDA Re-inspection of Decatur Facility
12 déc. 2016 07h00 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) conducted...
Akorn Launches Ibuprofen Oral Suspension
29 nov. 2016 07h30 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has launched the prescription version of Ibuprofen...
Akorn Invalidates Durezol® Patent Via Inter Partes Review Proceeding
28 nov. 2016 17h15 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that on November 22, 2016, the Patent Trial and Appeal...
Akorn to Present at Piper Jaffray 28th Annual Healthcare Conference
16 nov. 2016 08h30 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn’s Chief Financial Officer, Duane...
Akorn Provides Third Quarter 2016 Results
03 nov. 2016 07h05 HE
|
Akorn, Inc.
- Q3 2016 Revenue Increase of 11% to $284 million - - Q3 2016 GAAP EPS of $0.38; Adjusted Q3 2016 EPS of $0.56 - - Updates 2016 Revenue, EPS and Adjusted EBITDA Guidance - - Repurchased $25 Million...
Akorn Announces Third Quarter 2016 Earnings Release and Conference Call Information
13 oct. 2016 08h30 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on...